|
Market Closed -
London S.E.
11:35:01 2026-11-06 EST
|
5-day change | 1st Jan Change | ||
| 77.50 GBX | 0.00% |
|
-6.06% | -3.73% |
| 10-15 | Arecor Therapeutics Obtains Patents in Europe, US, India, for Rapid-acting Insulin | MT |
| 10-15 | Arecor Therapeutics Plc Strengthens Patent Protection For Its Proprietary AT278 Product | CI |
Company Valuation: Arecor Therapeutics plc
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 111.3 | 73.48 | 55.89 | 27.75 | 30.39 | 35.11 | - |
| Change | - | -34% | -23.94% | -50.35% | 9.52% | 15.51% | - |
| Enterprise Value (EV) 1 | 93.02 | 60.68 | 49.14 | 24.49 | 24.36 | 29.54 | 34.86 |
| Change | - | -34.77% | -19.01% | -50.16% | -0.54% | 21.26% | 18% |
| P/E | -14.8x | -7.5x | -6.52x | -2.37x | - | - | - |
| PBR | - | 4.21x | 5.87x | 4.21x | 4.92x | 6.36x | -43.3x |
| PEG | - | -0.4x | 0.5x | -0.2x | - | - | - |
| Capitalization / Revenue | 96.1x | 30.6x | 12.2x | 5.49x | 9.61x | 117x | 171x |
| EV / Revenue | 80.3x | 25.3x | 10.7x | 4.85x | 7.7x | 98.5x | 170x |
| EV / EBITDA | -14.8x | -5.9x | -5.66x | -3.52x | -6.95x | -5.56x | -6.23x |
| EV / EBIT | -14.4x | -5.71x | -5.36x | -3.31x | 36.5x | -5.11x | -5.76x |
| EV / FCF | - | -5.48x | -8.2x | -2.67x | -9.9x | -6.09x | -7.02x |
| FCF Yield | - | -18.3% | -12.2% | -37.5% | -10.1% | -16.4% | -14.3% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -0.27 | -0.32 | -0.28 | -0.31 | - | - | - |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 1.158 | 2.403 | 4.573 | 5.053 | 3.163 | 0.3 | 0.205 |
| EBITDA 1 | -6.268 | -10.29 | -8.679 | -6.963 | -3.506 | -5.311 | -5.599 |
| EBIT 1 | -6.439 | -10.63 | -9.175 | -7.409 | 0.667 | -5.786 | -6.05 |
| Net income | -6.169 | -9.26 | -8.554 | -10.24 | - | - | - |
| Net Debt 1 | -18.32 | -12.81 | -6.752 | -3.257 | -6.032 | -5.567 | -0.2488 |
| Reference price 2 | 4.0000 | 2.4000 | 1.8250 | 0.7350 | 0.8050 | 0.7750 | 0.7750 |
| Nbr of stocks (in thousands) | 27,835 | 30,618 | 30,627 | 37,757 | 37,757 | 45,301 | - |
| Announcement Date | 4/25/22 | 4/20/23 | 5/16/24 | 4/22/25 | 4/13/26 | - | - |
1GBP in Million2GBP
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | 98.47x | -5.56x | -.--% | 47.3M | |
| 18.32x | 6.97x | 13.35x | 1.63% | 69.4B | |
| 30.72x | 8.25x | 27.72x | 0.05% | 57.24B | |
| 39.18x | 6.93x | 20.69x | 0.83% | 57.62B | |
| 34.57x | 3.29x | 14.19x | -.--% | 43.65B | |
| 51.08x | 5.91x | 32.37x | -.--% | 44.03B | |
| -18.44x | 177.78x | -19.56x | -.--% | 38.08B | |
| 36.57x | 9x | 23.45x | 0.36% | 36.31B | |
| 44.16x | 7.87x | 26.34x | -.--% | 32.61B | |
| 29.41x | 6.22x | 16.14x | -.--% | 25.47B | |
| Average | 29.51x | 33.07x | 14.91x | 0.29% | 40.45B | |
| Weighted average by Cap. | 29.33x | 22.93x | 17.62x | 0.44% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AREC Stock
- Valuation Arecor Therapeutics plc
Select your edition
All financial news and data tailored to specific country editions
